Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia

International Journal of Neuropsychopharmacology

Volumn 1, Issue 2, 1998, Pages 131-135

  Heresco Levy, Uriel ^a,b   Javitt, Daniel C ^c,d   Ermilov, Marina ^a   Silipo, Gail ^c,d   Shimoni, Jonathan ^a  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

D cycloserine; N methyl D aspartate receptor; Negative symptoms; Schizophrenia

Indexed keywords

EID: 0001182422     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145798001242     Document Type: Article

References (16)

1. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994). D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. Journal of Neural Transmission 95, 105-111.
2. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). A dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry 152, 1213-1215.
3. Goff DC, Tsai G, Manoach DS, Flood J, Darby D, Coyle JT (1996). D-cycloserine added to clozapine for patients with schizophrenia. American Journal of Psychiatry 153, 1628-1630.
4. Guy W (Ed.), (1976). ECDEU Assessment Manual for Psychopharmacology. Washington DC: US Department of Health, Education and Welfare, pp. 534-537.
5. Hamilton M (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62.
6. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D (1996). Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. British Journal of Psychiatry 169, 610-617.
7. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. (In Press). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Archives of General Psychiatry.
8. Javitt DC, Zukin S (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148, 1301-1308.
9. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry 151, 1234-1236.
10. Kay SR, Opler LA, Fiszbein A (1987). Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, CA: Social and Behavioural Sciences Documents.
11. Rosse RB, Fay-McCarthy M, Kendrick K, Davis R, Deutsch S (1996). D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clinical Neuropharmacology 19, 444-450.
12. Simeon J, Fink M, Itil T, Ponce D (1970). D-cycloserine therapy of psychosis by symptom provocation. Comprehensive Psychiatry 11, 80-88.
13. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplement 212, 11-19.
14. Thompson LT, Moskal JR, Disterhoft JE (1992). Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 356, 638-641.
15. van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS (1996). Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biological Psychiatry 40, 1298-1300.
16. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lonthorn TH (1990). D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Research 510, 158-160.